Drug intelligence / Profile preview

Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula

Development stage: Approved
Lead developer: Moderna
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intramuscular

Overview

Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula is an updated mRNA-based monovalent vaccine developed by Moderna in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA). This formulation specifically targets the KP.2 strain, a variant of the SARS-CoV-2 Omicron JN.1 lineage. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver messenger RNA (mRNA) that encodes the spike glycoprotein of the KP.2 variant. Upon intramuscular administration, the mRNA directs host cells to express the spike protein, which subsequently induces a robust immune response, including the production of neutralizing antibodies and cellular immunity. This updated version was approved by the FDA in August 2024 to provide enhanced protection against circulating variants for the 2024-2025 respiratory virus season.

Brand names: Spikevax
Other names: Moderna KP.2-adapted monovalent vaccineSpikevax KP.2-adapted monovalent vaccineModerna COVID-19 Vaccine (2024-2025 Formula)

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula.